Cross-sectional study about primary health care professionals views on the inclusion of the vaccine against human papillomavirus in the vaccine schedules

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

(2014) Paulo S Naud et al.   Human Vaccines & Immunotherapeutics

Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: The CLEOPATRE study

(2012) Xavier Castellsagué et al.   JOURNAL OF MEDICAL VIROLOGY

End-of-study safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

(2011) X Castellsagué et al.   BRITISH JOURNAL OF CANCER

Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention

(2011) Laia Alemany et al.   GYNECOLOGIC ONCOLOGY

Considerations on the clinical application of the human papillomavirus vaccine in Spain

(2011) Javier Cortés et al.   Human vaccines & immunotherapeutics

Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine

(2011) C. Chao et al.   JOURNAL OF INTERNAL MEDICINE

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

(2011) Cosette M Wheeler et al.   LANCET ONCOLOGY

Knowledge and Concerns Related to the Human Papillomavirus Vaccine Among Underserved Latina Women

(2010) Justine P. Wu et al.   Journal of Lower Genital Tract Disease

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

(2010) Silvia de Sanjose et al.   LANCET ONCOLOGY

Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆

(2009) Marie-Pierre David et al.   GYNECOLOGIC ONCOLOGY

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

(2009) Nubia Muñoz et al.   LANCET

Screening, prevention and treatment of cervical cancer—A global and regional generalized cost-effectiveness analysis

(2009) Gary Michael Ginsberg et al.   VACCINE

Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far

(2009) Theodoros Agorastos et al.   VACCINE

Literature review of human papillomavirus vaccine acceptability among women over 26 years

(2009) Lora L. Black et al.   VACCINE

Epidemiology and cost of treatment of genital warts in Spain

(2008) Xavier Castellsagué et al.   EUROPEAN JOURNAL OF PUBLIC HEALTH